# To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema

> **NCT02462304** · PHASE4 · UNKNOWN · sponsor: **The University of Hong Kong** · enrollment: 60 (estimated)

## Conditions studied

- Diabetic Macula Edema

## Interventions

- **PROCEDURE:** End-Point-Management grid laser
- **DRUG:** ranibizumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT02462304
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-06
- **Primary completion:** 2017-06
- **Final completion:** 2017-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2016-04-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02462304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02462304, "To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02462304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*